Among Patients with Mild/moderate
Hemophilia, <15% Develop Inhibitors
Inhibitors develop when the body’s immune system ceases to accept clotting factor as a normal component of blood and attempts to destroy it with antibodies. These antibodies to factor negate its effectiveness, making it increasingly difficult to stop bleeding episodes. As such, developing an inhibitor is one of the most serious and costly complications of hemophilia.
Overall, approximately 15% to 20% of people with hemophilia will develop an inhibitor; patients with mild-to-moderate disease demonstrate a decreased likelihood of developing inhibitors compared to those with severe disease.